Guizhou Yibai Pharmaceutical Co., Ltd. (600594.SS) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-26). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. 600594.SS files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 21.00% | 30.00% | Pass |
| Interest-bearing investments | 13.28% | 30.00% | Pass |
| Non-permissible income | 0.20% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 20.54% | 33.00% | Pass |
| Interest-bearing investments | 12.99% | 33.00% | Pass |
| Non-liquid assets | 82.15% | at least 20.00% | Pass |
| Non-permissible income | 0.20% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 20.54% | 33.33% | Pass |
| Cash + interest-bearing securities | 12.99% | 33.33% | Pass |
| Accounts receivable | 17.85% | 33.33% | Pass |
| Non-permissible income | 0.20% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 20.54% | 33.33% | Pass |
| Cash + interest-bearing securities | 12.99% | 33.33% | Pass |
| Accounts receivable | 17.85% | 50.00% | Pass |
| Non-permissible income | 0.20% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 20.11% | 33.00% | Pass |
| Cash + interest-bearing securities | 12.72% | 33.00% | Pass |
| Accounts receivable | 4.76% | 33.00% | Pass |
| Non-permissible income | 0.20% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 18.84% | 33.00% | Pass |
| Cash + interest-bearing securities | 11.92% | 49.00% | Pass |
| Accounts receivable | 4.46% | 49.00% | Pass |
| Non-permissible income | 0.20% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 18.84% | 33.33% | Pass |
| Cash + interest-bearing securities | 11.92% | 33.33% | Pass |
| Accounts receivable | 16.38% | 49.00% | Pass |
| Non-permissible income | 0.20% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 45.70 | NEUTRAL |
| Stochastic %K (14) | 5.06 | BUY |
| CCI (20) | -122.28 | BUY |
| Williams %R (14) | -94.94 | BUY |
| MACD (12,26,9) | -0.05 | SELL |
| ROC (10) | -9.31 | SELL |
| Momentum (10) | -0.38 | SELL |
| EMA (10) | 3.85 | SELL |
| SMA (10) | 3.90 | SELL |
| EMA (20) | 3.85 | SELL |
| SMA (20) | 3.92 | SELL |
| EMA (30) | 3.81 | SELL |
| SMA (30) | 3.84 | SELL |
| EMA (50) | 3.75 | SELL |
| SMA (50) | 3.67 | SELL |
| EMA (100) | 3.75 | SELL |
| SMA (100) | 3.67 | SELL |
| EMA (200) | 3.93 | SELL |
| SMA (200) | 3.91 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells novel pharmaceutical products in China. The company offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, dripping pills, and oral solutions in the areas of tumor system, cerebrovascular and cardiovascular, respiratory system, rheumatic bone, digestive system, pediatric, anti-infection, anti-inflammatory, gynecological, tonic, oncology, orthopedics, gastroenterology, andrology and urology. Guizhou Yibai Pharmaceutical Co., Ltd. was founded in 1995 and is based in Guiyang, China.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.